Sewer epidemiology mass balances for assessing the illicit use of methamphetamine, amphetamine and tetrahydrocannabinol

Science of the Total Environment

Volumn 421-422, Issue , 2012, Pages 144-162

  Khan, Usman ^a   Nicell, Jim A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Amphetamine; Enantiomers; Methamphetamine; Sewer epidemiology; Tetrahydrocannabinol; Wastewater

Indexed keywords

AMPHETAMINE; DRUG RESIDUE; GENERAL SOURCE; ILLICIT DRUG; MASS BALANCE; METABOLIC CAPACITIES; METHAMPHETAMINE; MULTI-CRITERIA EVALUATION; SUBSTANCE FLOW ANALYSIS; TETRAHYDROCANNABINOL;

DISEASES; ENANTIOMERS; EPIDEMIOLOGY; EXTRAPOLATION; WASTEWATER;

SEWERS;

AMPHETAMINE; DRUG RESIDUE; METHAMPHETAMINE; TETRAHYDROCANNABINOL;

CONCENTRATION (COMPOSITION); DRUG; EPIDEMIOLOGY; MASS BALANCE; WASTEWATER;

ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG DISPOSITION; DRUG EXCRETION; DRUG RELEASE; ENANTIOMER; ENVIRONMENTAL PARAMETERS; FECES; FLOW MEASUREMENT; MASS BALANCE; METABOLIC CAPACITY; METABOLITE; PRIORITY JOURNAL; SEWER;

AMPHETAMINE; AMPHETAMINE-RELATED DISORDERS; HUMANS; MARIJUANA ABUSE; METHAMPHETAMINE; MODELS, THEORETICAL; SEWAGE; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS; TETRAHYDROCANNABINOL;

EID: 84858295922     PISSN: 00489697     EISSN: 18791026     Source Type: Journal    
DOI: 10.1016/j.scitotenv.2012.01.020     Document Type: Article

References (162)

1. Abraham T.T., Lowe R.H., Pirnay S.O., Darwin W.D., Huestis M.A. Simultaneous GC-EI-MS determination of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human urine following tandem enzyme-alkaline hydrolysis. J Anal Toxicol 2007, 31:477-485.
2. ACD Labs I-Lab 2.0 2011, ACD Labs, Toronto, Available at:. http://weblab.acdlabs.com/iLab2/.
3. ACMD Methamphetamine review 2005, AMCD (Advisory Council on the Misuse of Drugs, London.
4. Apoteket A.B. Total sale of medicinal products for 2006-08 [in Swedish] 2009, Apoteket AB, Stockholm.
5. Atha M.J. Cannabis use in Britain 2005, IDMU (Independent Drug Monitoring Unit), London.
6. Azzaro A.J., Ziemniak J., Kemper E., Campbell B.J., van Den Berg C. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol 2007, 47(10):1256-1267.
7. Baker D.R., Kasprzyk-Hordern B. Critical evaluation of methodology commonly used in sample collection, storage and preparation for the analysis of pharmaceuticals and illicit drugs in surface water and wastewater by solid phase extraction and liquid chromatography-mass spectrometry. J Chromatogr A 2011, 44(1218):8036-8059.
8. Baker D.R., Kasprzyk-Hordern B. Multi-residue determination of the sorption of illicit drugs and pharmaceuticals to wastewater suspended particulate matter using pressurised liquid extraction, solid phase extraction and liquid chromatography coupled with tandem mass spectrometry. J Chromatogr A 2011, 44(1218):7901-7913.
9. Barnes A.J., Smith M.L., Kacinko S.L., Schwilke E.W., Cone E.J., Moolchan E.T., et al. Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. Clin Chem 2008, 54:172-180.
10. Beckett H., Rowland M. Urinary excretion kinetics of amphetamine in man. J Pharm Pharmacol 1965, 17(10):628-639.
11. Beckett H., Rowland M. Urinary excretion kinetics of methylamphetamine in man. J Pharm Pharmacol 1965, 17(S1):109-114.
12. Beckett H., Rowland M., Turner P. Influence of urinary pH on excretion of amphetamine. Lancet 1965, 285(7380):303.
13. Beckett H., Brookes L.G., Shenoy E.V.B. Urinary excretion of the drug and its main metabolite in man, after the administration of (±), (+), and (-) ethylamphetamine. J Pharm Pharmacol 1969, 21:151-156.
14. Bisceglia K. Occurrence and fate of pharmaceuticals, illicit drugs, and other emerging contaminants in natural and engineered environments [PhD Thesis]. Baltimore: John Hopkins University; 2010.
15. Bouchard M. Towards a realistic method to estimate cannabis production in industrialized countries. Contemp Drug Prob 2008, 35:291-320.
16. Brenneisen R., Meyer P., Chtioui H., Saugy M., Kamber M. Plasma and urine profiles of δ9-tetrahydrocannabinol and its metabolites 11-hydroxy-δ9-tetrahydrocannabinol and 11-nor-9-carboxy-δ9-tetrahydrocannabinol after cannabis smoking by male volunteers to estimate recent consumption by athletes. Anal Bioanal Chem 2010, 396:2493-2502.
17. Caldwell J. The metabolism of amphetamines in mammals. Drug Metab Rev 1976, 5(2):219-280.
18. 14C) methamphetamine in man, the guinea pig and the rat. Biochem J 1972, 129(1):11-22.
19. 14C]amphetamine in urine in man. Biochem J 1972, 129(1):23-24.
20. Chan K.H., Hsu M.C., Tseng C.Y., Chu W.L. Famprofazone use can be misinterpreted as methamphetamine abuse. J Anal Toxicol 2010, 34(6):347-353.
21. Cho A.K. Ice: a new dosage form of an old drug. Science 1990, 249(4969):631-634.
22. Clements K.W., Zhao X. Economics and marijuana: consumption, pricing and legalization 2009, Cambridge University Press, Cambridge.
23. Cody J.T. Enantiomeric composition of amphetamine and methamphetamine derived from the precursor compound famprofazone. Forensic Sci Int 1996, 80(3):S189-S199.
24. Cody J.T. Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results. J Occup Environ Med 2002, 44(5):435-450.
25. Cody J.T. Amphetamines. Handbook of analytical separations 2008, vol 6:127-174. Elsevier, Amsterdam, The Netherlands. 10.1016/S1567-7192(06)06003-7. M.J. Bogusz (Ed.).
26. Cody J.T., Valtier S. Detection of amphetamine following administration of fenproporex. J Anal Toxicol 1996, 20(6):425-431.
27. Cody J.T., Valtier S. Detection of amphetamine and methamphetamine following administration of benzphetamine. J Anal Toxicol 1998, 22(4):299-309.
28. Cody J.T., Valtier S. A gas chromatography-mass spectrometry method for the quantitation of clobenzorex. J Anal Toxicol 1999, 23(7):603-608.
29. Cody J.T., Valtier S., Nelson S.L. Amphetamine enantiomer excretion profile following administration of Adderall. J Anal Toxicol 2003, 27:485-492.
30. Cone E.J., Johnson R.E., Paul B.D., Mell L.D., Mitchell J. Marijuana-laced brownies: behavioral effects, physiologic effects, and urinalysis in humans following ingestion. J Anal Toxicol 1988, 12:169-175.
31. Cook C.E. Pyrolytic characteristics, pharmacokinetics, and bioavailability of smoked heroin, cocaine, phencyclidine, and methamphetamine. NIDA Res Monogr 1991, 115:6-23.
32. Cook C.E., Jeffcoat A.R., Sadler B.M., Hill J.M., Voyksner R.D., Pugh D.E., et al. Pharmacokinetics of oral methamphetamine and effects of repeated daily dosing in humans. Drug Metab Dispos 1992, 20(6):856-862.
33. Cook C.E., Jeffcoat A.R., Hill J.M., Pugh D.E., Patetta P.K., Sadler B.M., et al. Pharmacokinetics of methamphetamine self-administered to human subjects by smoking S-(+)-methamphetaminehydrochloride. Drug Metab Dispos 1993, 21(4):717-723.
34. D'Ascenzo G., Di Corcia A., Gentili A., Mancini R., Mastropasqua R., Nazzari M., et al. Fate of natural estrogen conjugates in municipal sewage transport and treatment facilities. Sci Total Environ 2003, 302(1-3):199-209.
35. Daughton C.G. Illicit drugs in municipal sewage: proposed new non-intrusive tool to heighten public awareness of societal use of illicit/abused drugs and their potential for ecological consequences. Pharmaceuticals and personal care products in the environment: scientific and regulatory issues (Symposium Series 791) 2001, 348-364. American Chemical Society, Washington, D.C. C.G. Daughton, T.L. Jones-Lepp (Eds.).
36. Daughton C.G. Illicit drugs: contaminants in the environment and utility in forensic epidemiology. Rev Environ Contam Toxicol 2011, 210:59-110.
37. Daughton C.G., Ruhoy I.S. Environmental footprint of pharmaceuticals: the significance of factors beyond direct excretion to sewers. Environ Toxicol Chem 2009, 28(12):2495-2521.
38. Davis J.M., Kopin I.J., Lemberger L., Axelrod J. Effects of urinary pH on amphetamine metabolism. Ann NY Acad Sci 1971, 179:493-501.
39. DEA ARCOS report 7:U.S.A. summary of retail drug purchases 2006 2008, DEA (Drug Enforcement Administration, Springfield, Virginia.
40. DEA STRIDE data for 2006 2011, DEA (Drug Enforcement Administration, Springfield, Virginia.
41. Delbeke F.T., Debackere M. The influence of diuretics on the excretion and metabolism of doping agents. III. Etilamfetamine. Arzneimittelforschung 1986, 36:1413-1416.
42. Deo R.P., Halden R.U. Effect of sample filtration on the quality of monitoring data reported for organic compounds during wastewater treatment. J Environ Monit 2010, 12(2):478-483.
43. DKMA Statistics on medicinal products, 2005-2010 2010, DKMA (The Danish Medicines Agency, Copenhagen.
44. Dring L.G., Smith R.L., Williams R.T. The fate of amphetamine in man and other species. Biochem J 1970, 116:425-435.
45. Dring L.G., Franklin R.B., Williams R.T. The fate of amphetamine and norephedrine in the Tamarin monkey compared with man. West Afr J Pharmacol Drug Res 1975, 2(1):26-30.
46. EFSA Scientific opinion on the safety of hemp (Cannabis genus) for use as animal feed. EFSA (European Food Safety Authority) J 2011, 9(3). Available at:, (Last accessed: Sept 1, 2011). http://www.efsa.europa.eu/en/efsajournal/doc/2011.pdf.
47. 3H-fenetylline in man. Eur J Pharmacol 1970, 13(1):123-128.
48. EMCDDA Drug profiles 2010, EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), Lisbon.
49. EMCDDA Problem amphetamine and methamphetamine use in Europe 2010, EMCDDA (European Monitoring Centre for Drugs and Drug Addiction), Lisbon.
50. Fortenbery T.R., Bennett M. Opportunities for commercial hemp production. Appl Econ Perspect Pol 2004, 26(1):97-117. 10.1111/j.1467-9353.2003.00164.x.
51. Franco A., Trapp S. Estimation of the soil-water partition coefficient normalized to organic carbon for ionizable organic chemicals. Environ. Toxicol Chem 2008, 27:1995-2004.
52. Franco A., Fu W., Trapp S. Influence of soil pH on the sorption of ionizable chemicals: modeling advances. Environ. Toxicol Chem. 2009, 28(3):458-464.
53. Galanter M., Wyatt R.J., Lemberger L., Weingartner H., Vaughan T.B., Roth W.T. Effects on humans of 9-tetrahydrocannabinol administered by smoking. Science 1972, 176(4037):934-936.
54. George S., Braithwaite R.A. Using amphetamine isomer ratios to determine the compliance of amphetamine abusers prescribed dexedrine. J Anal Toxicol 2000, 24:223-227.
55. GIP GIP databank 2010, GIP (Genees-en hulpmiddelen Informatie Project), Diemen.
56. GLUMRB Recommended standards for wastewater facilities 2004, GLUMRB (Great Lakes-Upper Mississippi River Board of State and Provincial Public Health and Environmental Managers), Albany, Available at:, (Last accessed: Sept 1, 2011). http://10statesstandards.com/wastewaterstandards.html.
57. Griffiths P., Mravcik V., Lopez D., Klempova D. Quite a lot of smoke but very limited fire-the use of methamphetamine in Europe. Drug Alcohol Rev 2008, 27(3):236-242.
58. Gunne L.M. The urinary output of d- and l-amphetamine in man. Biochem Pharmacol 1967, 16(5):863-869.
59. Gustafson R.A., Kim I., Stout P.R., Klette K.L., George M.P., Moolchan E.T., et al. Urinary pharmacokinetics of 11-nor-9-carboxy-delta9-tetrahydrocannabinol after controlled oral delta9-tetrahydrocannabinol administration. J Anal Toxicol 2004, 28:160-167.
60. Hakkarainen P., Kainulainen H., Perälä J. Measuring the cannabis market in Finland: a consumption-based estimate. Contemp Drug Prob 2008, 35:321-345.
61. Halldin M.M., Carlsson S., Kanter S.L., Widman M., Agurell S. Urinary metabolites of delta 1-tetrahydrocannabinol in man. Arzneimittelforschung 1982, 32(7):764-768.
62. Harman C., Reid M., Thomas K.V. In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. Environ Sci Technol 2011, 45(13):5676-5682.
63. Harris D.S., Boxenbaum H., Everhart E.T., Sequeira G., Mendelson J.E., Jones R.T. The bioavailability of intranasal and smoked methamphetamine. Clin Pharmacol Ther 2003, 74(5):475-486.
64. Hasegawa M., Matsubara K., Fukushima S., Maseda C., Uezono T., Kimura K. Stereoselective analyses of selegiline metabolites: possible urinary markers for selegiline therapy. Forensic Sci Int 1999, 101(2):95-106.
65. Health Canada Drug product database 2010, Health Canada, Ottawa, Available at:, (Last accessed: Sept 1, 2011). http://webprod3.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp.
66. Holler J.M., Bosy T.Z., Dunkley C.S., Levine B., Past M.R., Jacobs A. δ9-Tetrahydrocannabinol content of commercially available hemp products. J Anal Toxicol 2008, 32:428-432.
67. Hollister L.E., Kanter S.L., Board R.D., Green D.E. Marihuana metabolites in urine of man. III. Unchanged delta-9-tetrahydrocannabinol. Res Comm Chem Pathol Pharmacol 1974, 8(4):579-584.
68. Huestis M.A., Mitchell J.M., Cone E.J. Urinary excretion profiles of 11-nor-9-carboxy-δ9-tetrahydrocannabinol in humans after single smoked doses of marijuana. J Anal Toxicol 1996, 20:441-445.
69. Hunt C.A., Jones R.T. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980, 215(1):35-44.
70. Hunt C.A., Jones R.T., Herning R.I., Bachman J. Evidence that cannabidiol does not significantly alter the pharmacokinetics of tetrahydrocannabinol in man. J Pharmacokinet Biopharm 1981, 9(3):245-260.
71. IMA Drug sales at the wholesale level in Iceland 2007-2009 2010, IMA (lyfjastofnun, Reykjavík.
72. INCB Psychotropic substances - technical reports 2010, INCB (International Narcotics Control Board), New York.
73. Inoue T., Suzuki S. The metabolism of 1-phenyl-2-(N-methyl-N-benzylamino)propane (benzphetamine) and 1-phenyl-2-(N-methyl-N-furfurylamino)propane (furfenorex) in man. Xenobiotica 1986, 16(7):691-698.
74. Inoue T., Suzuki S. The metabolism of dimethylamphetamine in rat and man. Xenobiotica 1987, 17(8):965-971.
75. Jirovsky D., Lemr K., Sevcik J., Smysl B., Stransky Z. Methamphetamine-properties and analytical methods of enantiomer determination. Forensic Sci Int 1998, 96(1):61-70.
76. 14C]δ1-tetrahydrocannabinol. J Anal Toxicol 1990, 14(33):176-180.
77. Kanter S.L., Hollister L.E., Loeffler K.O. Marihuana metabolites in the urine of man VIII. Identification and quantitation of tetrahydrocannabinol by thin-layer chromatography and high-pressure liquid chromatography. J Chromatogr 1978, 150:233-237.
78. Karus M., Vogt D. European hemp industry: cultivation, processing and product lines. Euphytica 2004, 140:7-12.
79. Kasprzyk-Hordern B. Pharmacologically active compounds in the environment and their chirality. Chem Soc Rev 2010, 39(11):4466-4503.
80. Katagi M., Tatsuno M., Tsutsumi H., Miki A., Kamata T., Nishioka H., et al. Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in man. Xenobiotica 2002, 32(9):823-831.
81. Khan U., Nicell J.A. Refined sewer epidemiology mass balances and their application to heroin, cocaine and ecstasy. Environ Int 2011, 37:1236-1252.
82. Kilmer B., Pacula R.L. Estimating the size of the global drug market: a demand-side approach. Report 2 2009, RAND, Santa Monica.
83. Kim I., Oyler J.M., Moolchan E.T., Cone E.J., Huestis M.A. Urinary pharmacokinetics of methamphetamine and its metabolite, amphetamine following controlled oral administration to humans. Ther Drug Monit 2004, 26(6):664-672.
84. Kitchen I., Tremblay J., Andre J., Dring L.G., Idle J.R., Smith R.L., et al. Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 1979, 9(7):397-404.
85. Krishnan S.M., Pennick M., Stark J.G. Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig 2008, 28(12):745-755.
86. Kruse D. Hemp food in the EU. Presentation given at the 8th International Conference of the European Industrial Hemp Association. Wesseling, Germany; May 18-19th 2011.
87. Lee J.S., Yang W.K., Han E.Y., Lee S.Y., Park Y.H., Lim M.A., et al. Monitoring precursor chemicals of methamphetamine through enantiomer profiling. Forensic Sci Int 2007, 173(1):68-72.
88. Leggett T. A review of the world cannabis situation. Bull Narc 2006, 58(1-2):1-155.
89. Legleye S., Ben Lakhdar C., Spilka S. Two ways of estimating the euro value of the illicit market for cannabis in France. Drug Alcohol Rev 2008, 27(5):466-472.
90. Lemberger L. Tetrahydrocannabinol metabolism in man. Drug Metab Dispos 1973, 1(1):461-468.
91. Lemberger L., Silberstein S.D., Axelrod J., Kopin I.J. Marihuana: studies on the disposition and metabolism of tetrahydrocannabinol in man. Science 1970, 170:1320-1322.
92. Lemberger L., Tamarkin N.R., Axelrod J., Kopin I.J. Delta-9-tetrahydrocannabinol: metabolism and disposition in long-term marihuana smokers. Science 1971, 173(3991):72-77.
93. Lemberger L., Axelrod J., Kopin I.J. Metabolism and disposition of tetrahydrocannabinols in näive subjects and chronic marijuana users. Ann NY Acad Sci 1971, 191:142-154.
94. Li L., Everhart T., Jacob P., Jones R., Mendelson J. Stereoselectivity in the human metabolism of methamphetamine. Br J Clin Pharmacol 2010, 69(2):187-192.
95. Li L., Lopez J.C., Galloway G.P., Baggott M.J., Everhart T., Mendelson J. Estimating the intake of abused methamphetamines using experimenter-administered deuterium labeled R-methamphetamine: selection of the R-methamphetamine dose. Ther Drug Monit 2010, 32(4):504-507.
96. Lindgren J.E., Ohlsson A., Agurell S., Hollister L., Gillespie H. Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis. Psychopharmacology 1981, 74(3):208-212.
97. Martyny J.W., Arbuckle S.L., McCammon S.C., Nicola E., Van Dyke M. Methamphetamine contamination on environmental surfaces caused by simulated smoking of methamphetamine. J Chem Health Safety 2008, 15(5):25-31.
98. Massart D.L., Vandeginste B.G.M., Buydens L.M.C., De Jong S., Lewi P.J., Smeyers-Verbeke J. Handbook of chemometrics and qualimetrics 1997, Elsevier, New York.
99. McKetin R., McLaren J., Kelly E. The Sydney methamphetamine market: patterns supply, use personal harms and social consequences. Monograph 2005, no. 13. National Drug Law Enforcement Research Fund.
100. McKetin R., Kozel N., Douglas J., Ali R., Vicknasingam B., Lund J., et al. The rise of methamphetamine in Southeast and East Asia. Drug Alcohol Rev 2008, 27(3):220-228.
101. Mendelson J., Jones R.T., Upton R., Jacob P. Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther 1995, 57(5):559-568.
102. Mendelson J.E., McGlothlin D., Harris D.S., Foster E., Everhart T., Jacob P., et al. The clinical pharmacology of intranasal l-methamphetamine. BMC Clin Pharmacol 2008, 8:4. (online only). 10.1186/1472-6904-8-4.
103. Metcalfe C., Tindale K., Li H., Rodayan A., Yargeau V. Illicit drugs in Canadian municipal wastewater and estimates of community drug use. Environ Pollut 2010, 158(10):3179-3185.
104. Nagai T., Kanaya H., Matsushima K., Kamiyama S. Time-lapse changes of d- and l-enantiomers of racemic (±)-ethylamphetamine in human urine. J Anal Toxicol 1997, 21:112-115.
105. NDIC National threat assessment methamphetamine assessment 2006, NDIC (National Drug Intelligence Center), Johnstown, PA.
106. NDIC National threat assessment methamphetamine assessment 2010 2010, NDIC (National Drug Intelligence Center), Johnstown, PA.
107. NDRI-AIC National amphetamine-type stimulant strategy background paper: monograph 2007, NDRI-AIC (National Drug Research Institute Australian Institute of Criminology), Canberra.
108. Neugebauer M., Khedr A., El Rabbat N., El Kommos M., Saleh G. Stereoselective metabolic study of famprofazone. Biomed Chromatogr 1997, 11:356-361.
109. Nickel B., Niebch G., Peter G., von Schlichtegroll A., Tibes U. Fenetylline: new results on pharmacology, metabolism and kinetics. Drug Alcohol Depend 1986, 17(2-3):235-257.
110. NIPH Drug consumption in Norway 2005-2009 2010, NIPH (Norwegian Institute of Public Health, Oslo.
111. Oh E.S., Hong S.K., Kang G.I. Plasma and urinary concentrations of methamphetamine after oral administration of famprofazone to man. Xenobiotica 1992, 22(3):377-384.
112. Ohlsson A., Lindgren J.-E., Wahlén A., Agurell S., Hollister L.E., Gillespie H.K. Single dose kinetics of deuterium labelled δ1-tetrahydrocannabinol in heavy and light cannabis users. Biomed Mass Spectrom 1982, 9(1):6-10.
113. Perez-Reyes M., Lipton M.A., Timmons M.C., Wall M.E., Brine D.R., Davis K.H. Pharmacology of orally administered delta-9-tetrahydrocannabinol. Clin Pharmacol Ther 1973, 14:48-55.
114. Phillips P.J., Smith S.G., Kolpin D.W., Zaugg S.D., Buxton H.T., Furlong E.T., et al. Pharmaceutical formulation facilities as sources of opioids and other pharmaceuticals to wastewater treatment plant effluents. Environ Sci Technol 2010, 44(13):4910-4916.
115. PLM Diccionario de especialidades farmaceuticas [in Spanish] 2009, Thomson.
116. Postigo C., Lopez de Alda M.J., Barcelo D. Drugs of abuse and their metabolites in the Ebro River basin: occurrence in sewage and surface water, sewage treatment plants removal efficiency, and collective drug usage estimation. Environ Int 2010, 36(1):75-84.
117. Qasim S.R. Wastewater treatment plants: planning, design and operation 1999, Florida, Boca Raton. 2nd ed.
118. Remberg G., Marsel J., Doering G., Spiteller G. Amphetamine, a metabolite of AN 1. Problems of doping analyses. Arch Toxikol 1972, 29(2):153-157.
119. 14C] prenylamine in man. Biomed Mass Spectrom 1977, 4(5):297-304.
120. Rendic S., Slavica M., Medic-Saric M. Urinary excretion and metabolism of orally administered mefenorex. Eur J Drug Metab Pharmacokinet 1994, 19(2):107-117.
121. Rowland M. Amphetamine blood and urine levels in man. J Pharm Sci 1969, 58(4):508-509.
122. SAMHSA The NSDUH report: state estimates of past year methamphetamine use 2006, SAMHSA (Substance Abuse and Mental Health Services Administration), Rockville, MD.
123. SAMHSA The DASIS report: primary methamphetamine/amphetamine admissions to substance abuse treatment: 2005 2008, SAMHSA (Substance Abuse and Mental Health Services Administration), Rockville, MD.
124. SAMHSA The NSDUH report: nonmedical use of Adderall among full-time college students 2009, SAMHSA (Substance Abuse and Mental Health Services Administration), Rockville, MD.
125. Sato M., Hida M., Nagase H. Analysis of dimethylamphetamine and its metabolites in human urine by liquid chromatography-electrospray ionization-mass spectrometry with direct sample injection. Forensic Sci Int 2002, 128(3):146-154.
126. Schep L.J., Slaughter R.J., Beasley D.M. The clinical toxicology of metamfetamine. Clin Toxicol 2010, 48(7):675-694.
127. Schlander M. Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription drug spending for children and adolescents: increasing relevance of health economic evidence. Child Adolesc Psychiatry Ment Health 2007, 1. [online only]. 10.1186/1753-2000-1-13.
128. Sekine H., Nakahara Y. Abuse of smoking methamphetamine mixed with tobacco. I. Inhalation efficacy and pyrolysis products of methamphetamine. J Forensic Sci 1987, 32(5):1271-1280.
129. Sever P.S., Caldwell J., Dring L.G., Williams R.T. The metabolism of amphetamine in dependent subjects. Eur J Clin Pharmacol 1973, 6:177-180.
130. Sever P.S., Dring L.G., Williams R.T. Urinary metabolites of p-hydroxyamphetamine in man, rat and guinea-pig. Xenobiotica 1976, 6(6):345-353.
131. Shima N., Tsutsumi H., Kamata T., Nishikawa M., Katagi M., Miki A., et al. Direct determination of glucuronide and sulfate of p-hydroxymethamphetamine in methamphetamine users' urine. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 830(1):64-70.
132. Shin H.S. Stereoselective metabolism of famprofazone in humans: N-dealkylation and beta- and p-hydroxylation. Chirality 1997, 9(1):52-58.
133. Shin H.S. Metabolism of selegiline in humans: identification, excretion, and stereochemistry of urine metabolites. Drug Metab Dispos 1997, 25(6):657-662.
134. Shumin Y., Changjiu Z., Kairong C. Detection of mesocarb in urine by HPLC and GC-MSD. 10th Cologne Workshop On Dope Analysis 7th to 12th June 1992 1993, 199-212. Sport und Buch Strauß, Köln. M. Donike, H. Geyer, A. Gotzmann, U. Mareck-Engelke, S. Ruth (Eds.).
135. Staack R.F., Fehn J., Maurer H.H. New designer drug para-methoxymethamphetamine (PMMA): studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 789(1):27-41.
136. Staub C. Chromatographic procedures for determination of cannabinoids in biological samples, with special attention to blood and alternative matrices like hair, saliva, sweat and meconium. J Chromatogr B Biomed Sci Appl 1999, 733(1-2):119-126.
137. Stillman R., Galanter M., Lemberger L., Fox S., Weingartner H., Wyatt R.J. Tetrahydrocannabinol (THC): metabolism and subjective effects. Life Sci 1976, 19(4):569-576.
138. Sweetman S.C. Martindale: the complete drug reference 2009, Pharmaceutical Press, London. 36th Edition.
139. Terzic S., Senta I., Ahel M. Illicit drugs in wastewater of the city of Zagreb (Croatia) - estimation of drug abuse in a transition country. Environ Pollut 2010, 158(8):2686-2693.
140. Tietz N.W. Clinical guide to laboratory tests 1995, W. B. Saunders, Philadelphia. 3rd ed.
141. Tognoni G., Morselli P.L., Garattini S. Amphetamine concentrations in rat brain and human urine after fenproporex administration. Eur J Pharmacol 1972, 20(1):125-126.
142. Tseng Y.L., Lin C.T., Wang S.M., Liu R.H. Famprofazone as the source of methamphetamine and amphetamine in urine specimen collected during sport competition. J Forensic Sci 2007, 52:479-486.
143. UNODC World drug report 2006-Annex 3 2006, UNODC (United Nations Office on Drugs and Crime), New York.
144. UNODC Global ATS assessment 2008, UNODC (United Nations Office on Drugs and Crime), New York.
145. US FDA Drugs at FDA 2010, US FDA (United States Federal Drug Administration, Available at:, (Last accessed Sept 1, 2011). http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
146. Valtier S., Cody J.T. Differentiation of clobenzorex use from amphetamine abuse using the metabolite 4-hydroxyclobenzorex. J Anal Toxicol 2000, 24(7):606-613.
147. van Nuijs A.L.N., Mougel J.-F., Tarcomnicu I., Bervoets L., Blust E., Jorens P.G., et al. Sewage epidemiology: a real-time approach to estimate the consumption of illicit drugs in Brussels, Belgium. Environ Int 2011, 37(3):612-621.
148. van Nuijs A.L.N., Castiglioni S., Tarcomnicu I., Postigo C., López De Alda M.J., Neels H., et al. Illicit drug consumption estimations derived from wastewater analysis: a critical review. Sci Total Environ 2011, 409:3564-3577.
149. Ventura R., Nadal T., Alcalde P., Segura J. Determination of mesocarb metabolites by high-performance liquid chromatography with UV detection and with mass spectrometry using a particle-beam interface. J Chromatogr 1993, 647:203-210.
150. Vree T.B., van Rossum J.M. Kinetics of metabolism and excretion of amphetamines in man. Amphetamines and related compounds 1970, 165-190. Raven Press, New York. E. Costa, S. Garattini (Eds.).
151. Wall M.E., Perez-Reyes M. The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 1981, 21:178S-89S.
152. Wall M.E., Brine D.R., Perez-Reyes M. Metabolism of cannabinoids in man. The pharmacology of marihuana 1976, 93-113. Raven Press, New York. M.C. Braude, S. Szara (Eds.).
153. Wall M.E., Sadler B.M., Brine D., Taylor H., Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol, in men and women. Clin Pharmacol Ther 1983, 34(3):352-363.
154. Wilens T.E., Adler L.A., Adams J., Sgambati S., Rotrosen J., Sawtelle R., et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47(1):21-31.
155. Williams P.L., Moffat A.C. Identification in human urine of delta 9-tetrahydrocannabinol-11-oic acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 1980, 32(7):445-448.
156. Yamamoto Y., Fukui Y., Kondo K. Determination of methamphetamine and amphetamine in urine and faeces by high performance liquid chromatography. Nippon Hoigaku Zasshi 1979, 33(2):105-110.
157. Yoshimura H., Yoshimitsu T., Yamada H., Koga N., Oguri K. Metabolic fate of fenetylline in rat and man. Xenobiotica 1988, 18(8):929-940.
158. Zabransky T. Methamphetamine in the Czech Republic. J Drug Issues 2007, 37(1):155-180.
159. Zhang Y., Wang Y., Zeng H. Analysis of four new drugs abuse in Beijing. Chin J Drug Depend 2008, 5:367-372.
160. Zuccato E., Chiabrando C., Castiglioni S., Calamari D., Bagnati R., Schiarea S., et al. Cocaine in surface waters: a new evidence-based tool to monitor community drug abuse. Environmental Health: A Global Access Science Source 2005, 4(14). (online only).
161. Zuccato E., Chiabrando C., Castiglioni S., Bagnati R., Fanelli R. Estimating community drug abuse by wastewater analysis. Environ Health Perspect 2008, 116(8):1027-1032.
162. Zuccato E., Castiglioni S., Tettamanti M., Olandese R., Bagnati R., Melis M., et al. Changes in illicit drug consumption patterns in 2009 detected by wastewater analysis. Drug Alcohol Depend 2011, 118(2-3):464-469.